Overall, the report, from the Tufts Center for the Study of Drug Development, found that new cancer drug approvals since 2010 have increased by 4 percent since the 1980s.
Drug costs are astronomical – this we know. But we don’t have a transparent, informed way of calculating – or understanding – the true costs of drug development, argued Dr. Jerry Avorn, a professor of pharmacoeconomics at Harvard University, in this week’s New England Journal of Medicine. And this ignorance may be helping big pharma inflate the price of drugs. He […]
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.